Abstract: Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract.

Abstract: The present invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure.

Abstract: The present invention relates to the use of gene activity markers for classification of patients suffering from infectious and non-infectious multiple organ failure, respectively. The present invention in particular relates to gene activity markers for classification of patients as “not infected without multiple organ failure” or as “not suffering from infectious multiple organ failure” or as “suffering from infectious multiple organ failure”, the gene activity markers being polynucleotides selected from the group consisting of: SEQ ID I.1, SEQ ID I.2, SEQ ID I.3, SEQ ID I.4, SEQ ID I.5, SEQ ID I.6, SEQ ID I.7, SEQ ID I.8 and SEQ ID I.9 or partial sequences thereof.

Abstract: Use of gene expression profiles obtained in vitro from a patient's sample for establishing the local infection of a “fever of unknown origin”, wherein the gene expression profiles are specific for local inflammations of a “fever of unknown origin”, such as peritonitis, pneumonia, endocarditis or infections of the urea tract.

Abstract: The present invention relates to the use of gene activity markers for classification of patients suffering from infectious and non-infectious multiple organ failure, respectively. The present invention in particular relates to gene activity markers for classification of patients as “not infected without multiple organ failure” or as “not suffering from infectious multiple organ failure” or as “suffering from infectious multiple organ failure”, the gene activity markers being polynucleotides selected from the group consisting of: SEQ ID 1.1, SEQ ID 1.2, SEQ ID 1.3, SEQ ID 1.4, SEQ ID 1.5, SEQ ID 1.6, SEQ ID 1.7, SEQ ID 1.8 and SEQ ID 1.9 or partial sequences thereof.

Abstract: The present invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure.

Abstract: The present invention relates to a method for in vitro detection of SIRS, sepsis and/or sepsis-like conditions. This method renders the evaluation of the severity and/or the therapeutic progress of sepsis and severe infections, in particular sepsis-like systemic infections possible. Further, the present invention relates to the use of recombinantly or synthetically prepared nucleic acid sequences or peptide sequences derived therefrom as calibrator in sepsis assays and/or for the evaluation of the effect and the toxicity during screening of the active agents and/or the preparation of therapeutics for the prevention and treatment of SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.

Abstract: The application relates to the use of a nucleic acid and/or protein chip comprising probe nucleic acids and/or probe proteins, which are specific for cellular stress, inflammatory and immune reactions, associated with stress, inflammatory and immune reactions, induced during acute phase responses or any combination thereof and which are immobilised on a carrier for the diagnosis of sepsis or sepsis related syndrome.

Abstract: The application relates to the use of a nucleic acid and/or protein chip comprising probe nucleic acids and/or probe proteins, which are specific for cellular stress, inflammatory and immune reactions, associated with stress, inflammatory and immune reactions, induced during acute phase responses or any combination thereof and which are immobilised on a carrier for the diagnosis of sepsis or sepsis related syndrome.